Skip to content
biotechnology hero image
biotechnology hero image

Biotechnology

Our team regularly advises clients developing biotech products in areas including biotechnology derived proteins (such as insulin), immunologicals (such as vaccines and allergens), blood or plasma derived products, and engineered tissues.

Our team benefits from having several members of the group who have completed degrees in subjects including molecular biology, biochemistry and genetics. This knowledge enables us to quickly grasp technical concepts and provide nuanced and tailored advice.

We closely follow new developments and emerging trends in the biotech market. For example, we have been following the emerging regulatory pathways for biosimilars and advising clients on appropriate strategies.

We have worked with many well-known companies on their biological products, including Pfizer, Novartis, Regeneron, Amgen and Roche.

News and insights

Scientist using a microscopic lens

Publications: 10 June 2022

Webinar: Creating cross-border value with patent term extensions and supplementary protection certificates

The selection of a patent for Patent Term Extension (PTE) or Supplementary Protection Certification (SPC) exclusivities is a critical decision for new drug products.

Read more
blister pack of pills

Publications: 09 June 2022

Webinar: "Reverse Payments" from Actavis to California AB 824: The Current State of Litigation Settlements in the Hatch-Waxman/BCPIA Space

Since the Supreme Court’s seminal decision in Actavis, brand and generic drug companies have been working within the antitrust framework laid out in that decision to craft patent litigation…

Read more

Blog Post: 23 March 2022

New decisions in Europe and the US in CRISPR/Cas9 patent dispute

CRISPR/Cas technology, also known as “genetic scissor”, is one of the most targeted and promising tools in gene technology. It allows targeted and extremely precise modification of the DNA in humans,…

Read more
Vials of medication during production

Publications: 15 December 2020

Healthcare accent is on smaller deals

Transactions in the U.S. healthcare space rebounded in autumn, although with a greater proportion of smaller deals than in recent years. 

Read more

Download our sector brochure

Life sciences A&O red molecules

Our Life Sciences and Healthcare sector focus 2022

Our global Life Sciences and Healthcare sector comprises a multi-disciplinary team. We act for companies and their investors across the industry, including in the pharmaceuticals, biotech, animal health, consumer health, med tech, and diagnostics sectors.